Regentis Biomaterials (NYSE American: RGNT) is moving its GelrinC cartilage repair platform forward on two fronts: a U.S. clinical trial and a European commercial launch. The company has surpassed 50% enrollment in its pivotal Phase III SAGE study, with recruitment completion targeted for the third quarter of 2026. Following that, a Pre-Market Approval (PMA) process is expected to begin by the end of 2027.
The U.S. trial is designed with a single-arm protocol that uses a historical microfracture control data package owned by Regentis. The company reports that the first 40 patients in the study closely match this control group, which could strengthen the validity of the trial results. This approach may accelerate the regulatory pathway by avoiding the need for a concurrent control arm.
Meanwhile, in Europe, where GelrinC already holds CE Mark approval, the company has initiated surgeon training at Humanitas Research Hospital in Milan. This training is part of an expanded clinical site network and is supported by a newly approved manufacturing process that increases yield by approximately 400%. This manufacturing scale-up is critical to meet potential demand as the product becomes more widely available.
GelrinC is a cell-free, off-the-shelf hydrogel implant designed for focal articular cartilage defects in the knee. Unlike cell-based therapies that require harvesting and expanding a patient's cells in a lab, GelrinC is ready for implantation in a procedure that takes about 10 minutes. The hydrogel forms a temporary matrix inside the defect, which is intended to support tissue regeneration.
The parallel advancement of clinical and commercial activities is significant for a development-stage medical technology company. Typically, regulatory approval and commercial revenue are separated by years, as trials must be completed, submissions reviewed, manufacturing scaled, surgeons trained, and distribution built. By running these workstreams concurrently, Regentis aims to compress the timeline between clinical validation and market adoption.
The company's progress in the U.S. trial and European commercialization could have implications for patients with knee cartilage defects, offering a potential off-the-shelf alternative to more complex cell-based treatments. For the industry, a successful PMA and commercial expansion could position GelrinC as a viable option in the cartilage repair market, potentially influencing treatment paradigms.
According to the company, the U.S. program is approaching a defining milestone. The SAGE study's completion and subsequent PMA submission will be critical steps in bringing GelrinC to the U.S. market. In Europe, the training of surgeons and the expansion of the clinical network are expected to support broader adoption of the product.
For more information, please refer to the company’s newsroom at https://ibn.fm/RGNT.
